title: Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome.
abstract: A patient with adrenocortical carcinoma presented with fever, leukocytosis, and increased acute phase reactants. The tumor was infiltrated with neutrophils. Immunohistochemical staining of the tumor showed positive signal for epithelial neutrophil-activating protein-78, an angiogenic and chemotactic CXC chemokine. Conditioned medium from tumor-derived cells (RL-251) showed high concentration of IL-8, epithelial neutrophil-activating protein-78, Gro alpha, and Gro gamma, angiogenic CXC chemokines with a potential role in tumorigenesis. An adrenal cancer/severe combined immunodeficiency mouse chimera was developed. Mice grew tumors rapidly, and circulating levels of IL-8 and epithelial neutrophil-activating protein-78 were detected. In contrast, animals transplanted with NCI-H295 cells, a nonchemokine-secreting cell line, grew tumors more slowly and did not have detectable chemokine levels. Similar to the patient, mice with RL-251 tumors developed marked leukocytosis and neutrophilia, and their tumors were infiltrated with neutrophils. Mice were passively immunized with epithelial neutrophil-activating protein-78 antisera. A marked decrease in tumor growth was observed. Potential for chemokine production by other adrenocortical tumors was investigated by RT-PCR in archival material. Six of seven adrenal carcinomas and one of three adenomas had cDNA for IL-8; six of seven carcinomas and the three adenomas had cDNA for epithelial neutrophil-activating protein-78. We concluded that the clinical presentation of this case resulted from increased tumor production of chemotactic chemokines. Through their angiogenic and chemotactic properties these chemokines may play an important role in adrenal tumorigenesis.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA. dschtein@umich.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Schteingart
authors.forename: T J
authors.initials: TJ
authors.lastname: Giordano
authors.forename: R S
authors.initials: RS
authors.lastname: Benitez
authors.forename: M D
authors.initials: MD
authors.lastname: Burdick
authors.forename: M N
authors.initials: MN
authors.lastname: Starkman
authors.forename: D A
authors.initials: DA
authors.lastname: Arenberg
authors.forename: R M
authors.initials: RM
authors.lastname: Strieter
mesh_terms: D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000236:Adenoma / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000601:surgery; D000306:Adrenal Cortex Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D000324:Adrenocorticotropic Hormone; D000368:Aged; D054365:Chemokine CXCL5; D019743:Chemokines, CXC / Q000032:analysis / Q000235:genetics*; D002940:Circadian Rhythm; D005334:Fever; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D007150:Immunohistochemistry; D016209:Interleukin-8 / Q000031:analogs & derivatives / Q000032:analysis / Q000235:genetics*; D007964:Leukocytosis; D008297:Male; D018375:Neutrophil Activation; D009504:Neutrophils / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013577:Syndrome; D014407:Tumor Cells, Cultured
chemical_list: D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; C486263:CXCL5 protein, human; D054365:Chemokine CXCL5; D019743:Chemokines, CXC; D016209:Interleukin-8; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone